Compare RLX Technology Inc (RLX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Sanofi SA — how do they compare? RLX Technology Inc trades at $2.02 (market cap $2.42B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 43.1× RLX Technology Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| RLX | SNY | |
|---|---|---|
Market Cap | $2.42B | $104.30B |
Sector | Technology | Health |
52-Week High | $2.73 | $52.34 |
52-Week Low | $1.79 | $41.33 |
Enterprise Value | $1.04B | $124.19B |
Dividend Yield | 5.05% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX trades at $2.01, up 0.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with a net income margin of 22.47% in 2026. Recent news highlights its Q2 2026 earnings call scheduled for August 14, 2026, focusing on European integration.
The outlook is mixed: strong international revenue growth and solid profitability support upside, but consecutive earnings misses and a single analyst's hold rating indicate caution. Key risks include regulatory scrutiny in the vaping industry and execution challenges in global markets.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
